Literature DB >> 7523381

The ubiquitously expressed Syp phosphatase interacts with c-kit and Grb2 in hematopoietic cells.

T Tauchi1, G S Feng, M S Marshall, R Shen, C Mantel, T Pawson, H E Broxmeyer.   

Abstract

The c-kit proto-oncogene encodes a transmembrane tyrosine kinase receptor, which is important for the normal development of hematopoietic cells, melanoblasts, and germ cells. Autophosphorylation of c-kit receptor on tyrosine creates binding sites for cellular src homology 2 (SH2)-containing signaling molecules. The discovery of phosphotyrosine phosphatases that contain SH2 domains suggests roles for these molecules in growth factor signaling pathways. We found that Syp, a phosphotyrosine phosphatase widely expressed in all the tissues in mammals, associates with c-kit receptor after activation with its ligand, steel factor, in the factor-dependent cell line, M07e. Both NH2-terminal and COOH-terminal SH2 domains of Syp, made as glutathione S-transferase fusion proteins, were able to bind to the activated c-kit receptor in vitro. Furthermore, Syp became marginally phosphorylated on tyrosine upon c-kit receptor activation, and tyrosine-phosphorylated Syp was found to be complexed with Grb2 in steel factor-stimulated M07e cells. Direct binding between Syp and Grb2 was also observed in vitro. Last, Ras and Raf interacts in vitro as a result of steel factor-stimulated Ras activation. These results suggest that Syp may be an important signaling component downstream of the c-kit receptor and involved in activation of the Ras signaling pathway in hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523381

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain.

Authors:  M Kozlowski; L Larose; F Lee; D M Le; R Rottapel; K A Siminovitch
Journal:  Mol Cell Biol       Date:  1998-04       Impact factor: 4.272

2.  Structural determinants of SHP-2 function and specificity in Xenopus mesoderm induction.

Authors:  A M O'Reilly; B G Neel
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

3.  A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development.

Authors:  C K Qu; Z Q Shi; R Shen; F Y Tsai; S H Orkin; G S Feng
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

Review 4.  The IRS-signalling system: a network of docking proteins that mediate insulin action.

Authors:  M F White
Journal:  Mol Cell Biochem       Date:  1998-05       Impact factor: 3.396

5.  Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression.

Authors:  A M Bennett; S F Hausdorff; A M O'Reilly; R M Freeman; B G Neel
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

6.  PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.

Authors:  Rebecca J Chan; Gen-Sheng Feng
Journal:  Blood       Date:  2006-10-19       Impact factor: 22.113

7.  C-kit expression in germinoma: an immunohistochemistry-based study.

Authors:  Hideo Nakamura; Hideo Takeshima; Keishi Makino; Jun-Ichi Kuratsu
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

8.  c-kit receptor signaling through its phosphatidylinositide-3'-kinase-binding site and protein kinase C: role in mast cell enhancement of degranulation, adhesion, and membrane ruffling.

Authors:  K Vosseller; G Stella; N S Yee; P Besmer
Journal:  Mol Biol Cell       Date:  1997-05       Impact factor: 4.138

9.  Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.

Authors:  F Schaper; C Gendo; M Eck; J Schmitz; C Grimm; D Anhuf; I M Kerr; P C Heinrich
Journal:  Biochem J       Date:  1998-11-01       Impact factor: 3.857

10.  Signal transduction of c-Kit receptor tyrosine kinase in CHRF myeloid leukemia cells.

Authors:  Sebastian Scholl; Cornelia Kirsch; Frank D Böhmer; Reinhard Klinger
Journal:  J Cancer Res Clin Oncol       Date:  2004-08-31       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.